You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 121 No. 9, September 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Correspondence
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Law and Medicine
 •Medical Ethics
 •Laser Surgery
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Subthreshold Laser Photocoagulation and Criminal Fraud

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Laser photocoagulation has evolved substantially since its introduction. Emphasis is now placed more on laser techniques that spare the retinal structures and limit collateral damage. Previously, laser surgeons used relatively intense yellow-white lesions that could easily be seen directly after placement, either for panretinal photocoagulation or for ablation of choroidal neovascular membranes. These lesions were all well above threshold, ie, beyond the intensity at which they would be barely detectable in the retina during treatment. Efforts to improve visual outcomes have incorporated substantially less intense lesions, including clinically undetectable subthreshold lesions. The effects of subthreshold laser treatment on drusen resorption in age-related macular degeneration is being studied as part of a clinical trial (Prophylactic Treatment of Age-Related Macular Degeneration).1 Such treatment has also been used for diabetic macular edema and even proliferative diabetic retinopathy.2 Proof of therapeutic efficacy of these interventions is not yet irrefutable, although a few early reports . . . [Full Text of this Article]

Thomas R. Friberg, MD
Pittsburgh, Pa

Johann Roider, MD
Kiel, Germany



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.